Robert Bonow, MD, the Max and Lilly Goldberg Distinguished Professor of Cardiology, has been named editor-in-chief of JAMA Cardiology, a new journal in the JAMA Network that will debut in 2016.
In a recent study, Shuang Zhang, a fourth year student in the Driskill Graduate Program in the Life Sciences (DGP), shed light on a molecule that mediates cross-talk between cardiac cells and immune cells after injury.
In a new study, patients treated with one-fourth of the dose of beta-blockers tested in large clinical trials had a 20 to 25 percent increase in survival, indicating that dosing likely needs to be personalized for patients to get the best benefit.
A new imaging technique that allows for visualization of blood flow in real-time revealed that abnormal blood flow from the two-flap valve in bicuspid aortic valve disease can create weakness in the aorta.
A study showed that an investigational drug, idarucizumab, reverses the anticoagulant effect of dabigatran, a blood thinning drug used for the prevention of stroke. This is the first test of this reversal agent in patients with bleeding or need for emergent surgery.
A new Northwestern Medicine research center funded by the American Heart Association will study links between dietary phosphate and heart disease, with a focus on reducing health disparities in minority populations.
By examining how loss of lung function between young adulthood and middle age associated with changes in the heart, Northwestern Medicine scientists identified two heart-lung phenotypes that may form the basis for diseases that develop later in life.
Enrollees in Feinberg’s Master of Science in Clinical Investigation (MSCI) program developed research projects including a yoga intervention for patients with Parkinson’s disease and a cardiovascular risk assessment for cholesterol guidelines.
Higher neighborhood segregation is associated with a higher risk of cardiovascular disease for blacks and a lower risk for whites, according to a recent Northwestern Medicine study.
Northwestern Medicine scientists used “big data” tools to classify for the first time three distinct categories of a common heart failure syndrome. The findings may be used to better predict how diverse patients will respond to treatments.